Contribute Try STAT+ Today

For some children with a certain type of brain tumor, treatment can mean surgery followed by multiple rounds of chemotherapy infusions to beat back the growth of their low-grade gliomas. A San Francisco startup hopes to change that trajectory with an oral therapy targeting specific proteins mutated in these cancers, part of a larger game plan to make precision treatments as available for kids with cancer as they are for adults.

Day One Biopharmaceuticals — named for the conversations clinicians have with parents when they first tell them their child has cancer and how they hope to treat it — announced on Thursday its first financing and its first drug candidate. Backed by $60 million from Canaan, Access Biotechnology, and Atlas Venture, the 25-person startup has struck a deal with Takeda Pharmaceutical (TAK) to acquire the rights to develop TAK-580, including certain rights previously licensed by Takeda from Sunesis Pharmaceuticals (SNSS). The drug candidate, renamed DAY101, is currently being tested in an early clinical trial to treat children with low-grade gliomas that have not responded to other treatments. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.